Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma

Journal of Medical Primatology

Volumn 29, Issue 3-4, 2000, Pages 240-247

  Dale, C Jane ^a,b   Zhao, Anne ^a,b   Jones, Stephen L ^c   Boyle, David B ^d   Ramshaw, Ian A ^e   Kent, Stephen J ^a,b  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CSL LIMITED   (Australia)

^d CSIRO   (Australia)

^e The Australian National University   (Australia)

Author keywords

CD69; Cellular immunity; ELISOT; Gamma assay; Interferon; Vaccine vectors

Indexed keywords

CD69 ANTIGEN; CYTOKINE; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT OUTCOME; VIRUS RECOMBINANT;

ANIMALIA; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA;

EID: 0033797658     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0684.2000.290317.x     Document Type: Article

References (39)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Inactivated SIV vaccines
3. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
4. In vivo adaptation of HIV-1 to replication in pigtailed macaques
5. Behavioural effects of simple manipulable environmental enrichment techniques on macaques
6. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation
7. Cytokines and reperfusion injury
8. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
9. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection
10. Development of a human gamma interferon enzyme immunoassay and comparison with tuberculin skin testing for detection of Mycobacterium tuberculosis infection
11. Lymphoproliferarive immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection
12. Randomised trial of MNrgp 120 HIV-1 vaccine in symptomless HIV-1 infection
13. Virus-specific T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
14. Early suppression of SIV replication by CD8 + nef-specific cytotoxic T cells in vaccinated macaques
15. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and B-chemokine production
16. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens
17. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
18. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees
19. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
20. Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination
21. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques
22. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
23. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques
24. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
25. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus
26. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
27. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
28. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults
29. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection
30. Vigorous HIV-1-specific CD4+ T cell responses with control of viremia
31. Inactivation of HIV-1 infectivity with preservation of conformational and functional integrity of virion surface proteins
32. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
33. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection
34. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160: A double blind controlled randomised study of safety and immunogenicity
35. Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques
36. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
37. Specific therapy regimes could lead to long-term immunological control of HIV
38. In vitro immunodiagnostic assays for bovine tuberculosis
39. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy